Sign In
Buy AFMD
$0.182
+0 (+0%)
At Close: Sep 16, 2025
Affimed N.V. (AFMD) Expected to Beat Earnings Estimates: Should You Buy?
04:05pm, Wednesday, 03'rd Nov 2021
Affimed N.V. (AFMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Affimed to Report Third Quarter 2021 Financial Results & Corporate Update on November 10, 2021
06:30am, Friday, 29'th Oct 2021
HEIDELBERG, Germany, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, tod
Affimed: Preparing For A Bullish 2022
09:09pm, Monday, 11'th Oct 2021
Affimed: Preparing For A Bullish 2022
HEIDELBERG, Germany, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, tod
Affimed N.V. (AFMD) CEO Adi Hoess on Q2 2021 Results - Earnings Call Transcript
02:24pm, Wednesday, 08'th Sep 2021
Affimed N.V. (AFMD) CEO Adi Hoess on Q2 2021 Results - Earnings Call Transcript
Affimed N.V. (AFMD) Reports Q2 Loss, Lags Revenue Estimates
10:15am, Wednesday, 08'th Sep 2021
Affimed N.V. (AFMD) delivered earnings and revenue surprises of -171.43% and -13.79%, respectively, for the quarter ended June 2021.
Affimed Reports Second Quarter 2021 Financial Results and Highlights Operational Progress
06:30am, Wednesday, 08'th Sep 2021
HEIDELBERG, Germany, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, to
Affimed to Present at Upcoming Investor Conferences
06:30am, Thursday, 26'th Aug 2021
HEIDELBERG, Germany, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, tod
Affimed to Report Second Quarter 2021 Financial Results & Corporate Update on September 8, 2021
06:30am, Monday, 23'rd Aug 2021
HEIDELBERG, Germany, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, tod
Will Affimed N.V. (AFMD) Report Negative Q2 Earnings?
04:47pm, Tuesday, 03'rd Aug 2021
Affimed N.V. (AFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
HEIDELBERG, Germany, July 30, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, ann
3 Former Penny Stocks With Bullish Analysts & Price Targets Up To 120%
11:51am, Friday, 23'rd Jul 2021
Former penny stocks biotech analysts are bullish on right now. The post 3 Former Penny Stocks With Bullish Analysts & Price Targets Up To 120% appeared first on Penny Stocks to Buy, Picks, News and In
3 Biotech Stocks That Could Double Soon
06:44am, Wednesday, 21'st Jul 2021
Wall Street analysts following these drugmakers think they can produce big gains in a short time frame.
Affimed: Remaining Bullish Despite Study Discontinuation
10:16pm, Thursday, 08'th Jul 2021
Affimed recently reported their Q1 earnings that revealed a solid beat on EPS and revenue. However, the company also announced that Genentech has stopped one of their partnered programs. Following the
Affimed: Current Fall And Future Prospects
11:01am, Wednesday, 07'th Jul 2021
Affimed did well in the last 12 months, but has been seeing a correction lately. Given a "data rich" 2021, the correction is not correct.
